Symlin Dose Titration Mitigates Hypoglycemia, Nausea, Amylin Says
This article was originally published in Pharmaceutical Approvals Monthly
Amylin’s recent Symlin NDA amendment shows that a dose titration regimen reduces the risks of nausea and hypoglycemia in type 1 and 2 diabetes patients, the firm reported June 15.
You may also be interested in...
FDA's internal review of the dosing instructions for Amylin's antidiabetic Symlin likely will revisit dosing-related concerns first identified during its NDA review
Amylin expects its hypoglycemia re-analysis to mitigate FDA’s concerns about its pending antidiabetic Symlin, the company says.